📢 Press release Framatome and IBA RadioPharma Solutions have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (²¹¹At), an alpha-emitting radioisotope across Europe and the United States. 🔗 Read the full press release here: https://lnkd.in/eim5egss
📣𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀: 𝗙𝗿𝗮𝗺𝗮𝘁𝗼𝗺𝗲 𝗮𝗻𝗱 𝗜𝗕𝗔 𝘁𝗼 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗮𝗻 𝗔𝘀𝘁𝗮𝘁𝗶𝗻𝗲-𝟮𝟭𝟭 𝗖𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗨𝗦𝗔 We are delighted to announce that IBA and Framatome signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (²¹¹At), an alpha-emitting radioisotope across Europe and the United States. Charles Kumps, President of IBA RadioPharma Solutions: "It is the start of what we believe will be a strong partnership with a shared goal: building a global, reliable industrial network for the timely production and commercialization of Astatine-211 compounds. By leveraging our combined expertise in cyclotron technology and in nuclear medicine, we are creating the critical infrastructure necessary to unlock the full potential of these groundbreaking therapies.” 👉 Read the Press Release → https://bit.ly/42HCejr #IBA #Astatine211 #TAT #radioisotope #Theranostic #Alpha